# Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

> **NCT01712126** · NA · COMPLETED · sponsor: **Roxane Laboratories** · enrollment: 40 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Irbesartan and Hydrochlorothiazide
- **DRUG:** Avalide

## Key facts

- **NCT ID:** NCT01712126
- **Lead sponsor:** Roxane Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712126, "Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01712126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*